Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156253 | 0.85 | ALDH1A1 (0.60) | TDP1ALDH1A1MAPTNOX4RGS12 | |
| SCHEMBL155359 | 0.85 | KMT2A (0.53) | TDP1ALDH1A1MAPTNOX4RGS12 | |
| SCHEMBL5692310 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTPOLBNPC1RAB9A | |
| SCHEMBL10825937 | 0.77 | TDP1 (0.48) | TDP1ALDH1A1MAPTAKR1C3POLB | |
| SCHEMBL1403591 | 0.77 | KDM4E (0.59) | ALDH1A1NOX4KDM4CKDM4EPPARA | |
| Hydrochloric Acid SCHEMBL17362383 | 0.76 | TDP1 (0.67) | TDP1ALDH1A1MAPTAKR1C3POLB | |
| SCHEMBL340537 | 0.75 | AKR1C3 (0.55) | ALDH1A1MAPTAKR1C3MEN1KMT2A | |
| SCHEMBL11367974 | 0.75 | PLK1 (0.51) | ALDH1A1MAPTKDM4CPPARACYP1A2 | |
| SCHEMBL851008 | 0.74 | ERCC1 (0.60) | TDP1ALDH1A1MAPTNOX4RGS12 | |
| SCHEMBL11666972 | 0.74 | PLK1 (0.56) | EGFRKDM4CPPARACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | claimed |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | LEE JUSTIN C (US) | 2016-02-18 | — | — | US | claimed |
| WO-2014169087-A2 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-16 | — | — | WO | claimed |
| US-20080138277-A1 | Delivery systems and methods for diagnosing and treating cardiovascular diseases | MEDSTAR HEALTH INC (US) | 2008-06-12 | — | — | US | claimed |
| EP-1866416-A2 | DELIVERY SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CARDIOVASCULAR DISEASES | Medstar Health Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006102395-A2 | DELIVERY SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CARDIOVASCULAR DISEASES | MEDSTAR HEALTH INC (US) | 2006-09-28 | — | — | WO | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2025085655-A1 | MEMBRANE COATED NANOPARTICLES FOR IMAGING | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2008067052-A2 | NONINVASIVE METHOD TO IDENTIFY NEUROACTIVE COMPOUNDS AND MEASURE THEIR PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008045952-A2 | PHOTORECEPTOR PRECURSOR CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | WO | disclosed |
| EP-1866416-A2 | DELIVERY SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CARDIOVASCULAR DISEASES | Medstar Health Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007029063-A2 | TREATMENT AND/OR PREVENTION OF PERVASIVE DEVELOPMENTAL DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-7129073-B2 | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways | THE ROCKEFELLER UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060223158-A1 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-05 | — | — | US | disclosed |
| WO-2006102395-A2 | DELIVERY SYSTEMS AND METHODS FOR DIAGNOSING AND TREATING CARDIOVASCULAR DISEASES | MEDSTAR HEALTH INC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | TDP1 722/4885ALDH1A1 4784/4885MAPT 832/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TDP1 2449/4885ALDH1A1 1161/4885MAPT 2171/4885 |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | CELF2, SMN1; SMN2, GRM8 | TDP1 954/4885ALDH1A1 2918/4885MAPT 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.